Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the “Company” or “Sona”), a nanotechnology company developing preclinical Targeted Hyperthermia (“THT”) therapy for colorectal cancer, is pleased to announce the selection of Minnetronix Medical to design the next generation of its infrared light device. The device will be used in Sona’s development of THT to transfer energy through infrared light to Sona’s proprietary biocompatible gold nanorods in tumors which will then convert the light energy into heat. The lighted device is designed to fit the auxiliary channel of sigmoidoscopes and colonoscopes used by gastroenterologist oncologists.
Minnetronix provides medical device design, development, and manufacturing services in several technology specialties, including optical devices, with expertise in complex optomechanics, lighting system design, optical system integration, power and heat; and LED and laser system design. Minnetronix has worked with hundreds of customers to design and manufacture advanced medical devices.
“The development of Sona Nanotech’s targeted hyperthermia therapy will rely on a technologically sophisticated illumination device that Minnetronix’s optics team has extensive development and manufacturing experience,” said Jeremy Maniak, CEO of Minnetronix.
“Our studies to date have shown the ability of infrared light to heat gold nanorods in vivo when applied externally to cancerous tumors in mice. using existing gastroenterology endoscopes, for our development of THT therapy against colorectal cancer”, Sona CEO David Regan commented.
David Regan, CEO
About Sona Nanotech Inc.
Sona Nanotech is a life science nanotechnology company that has developed several proprietary methods for manufacturing various types of gold nanoparticles. The core business conducted and intended to be pursued by Sona is the development and application of its proprietary technologies for use in multiplex diagnostic test platforms that will improve performance over existing tests in the market. Sona Nanotech’s gold nanorod particles are cetyltrimethylammonium (“CTAB”) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona’s gold nanotechnology may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to approval by various regulatory agencies, including Health Canada. and the FDA.
About Minnetronix Medical
Since 1996, Minnetronix Medical has accelerated breakthroughs in medical devices as the design, development and manufacturing partner for leading device companies worldwide. Today, through life cycle efficiencies, opportunity realization and increased utility, the company is creating value in key technology segments such as optical systems, RF energy, management fluids and gases, stimulation and active wearable devices. From design and manufacturing services to complete product solutions, Minnetronix has deep industry knowledge and intentional technical insight to bring better medical devices to market, faster.
CAUTION REGARDING FORWARD-LOOKING INFORMATION: This press release contains certain “forward-looking statements” under applicable Canadian securities laws, including statements regarding the prospects for the successful development of a technologically sophisticated lighting device. Forward-looking statements are necessarily based on a number of assumptions or estimates which, while believed to be reasonable, are subject to known and unknown risks, uncertainties and other factors which may cause actual results to differ. and future events differ materially from those expressed or implied. by these forward-looking statements, including the risk that Sona’s partner may not be able to successfully develop the technologically sophisticated lighting device that meets Sona’s requirements, Sona may not raise sufficient additional capital or develop the contemplated therapy . There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Sona disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.